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Abstract
The purpose of this meta-analysis was to examine the eﬃcacy of maintenance treatments for bipolar
disorder. Placebo-controlled or active comparator bipolar maintenance clinical trials of o6 months’ dur-
ation with at least 15 patients/treatment group were identiﬁed usingMedline, EMBASE, clinicaltrials.gov,
and Cochrane databases (1993 to July 2010). The main outcome measure was relative risk for relapse for
patients in remission. Twenty trials (5364 patients) were identiﬁed. Overall, lithium and quetiapine were
the most studied agents (eight and ﬁve trials, respectively). The majority of studies included patients who
had previously responded to treatment for an acute episode. All interventions, with the exception of
perphenazine+mood stabilizer, showed a relative risk for manic/mixed or depressive relapse below 1.0,
although there was variation in the statistical signiﬁcance of the ﬁndings vs. placebo. Nomonotherapy was
associated with a signiﬁcantly reduced risk for both manic/mixed and depressed relapse. Of the combi-
nation treatments, only quetiapine+lithium/divalproex, was associated with a signiﬁcantly reduced risk
vs. comparator (placebo+lithium/valproate) for relapse at both the manic/mixed and depressed poles of
bipolar illness. Limitations for the analysis include diﬀerences in study durations and deﬁnitions of re-
lapse. In conclusion, available maintenance therapies show considerable variation in eﬃcacy. The eﬃcacy
of lithium and divalproex has been conﬁrmed, but newer therapies, such as a number of atypical anti-
psychotics were also shown to be eﬀective in bipolar disorder. Eﬃcacy of all maintenance interventions
needs to be balanced against the safety and tolerability proﬁles of individual agents.
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Introduction
Bipolar disorder is a major mental health issue associ-
ated with considerable morbidity and mortality
(Hirschfeld & Vornik, 2005). It is characterized by
recurrent episodes of mania or hypomania and de-
pression, separated by periods of relatively normal
behaviour (Kasper, 2003; Oswald et al. 2007). In some
people, however, symptoms of mania and depression
may occur together in what is called a mixed bipolar
state. Treatments are available that can stabilize the
acute mood swings – mania, hypomania, depression
or mixed states – in bipolar disorders. However, be-
cause it is a recurrent illness, long-term prophylactic
maintenance treatment is usually recommended
(Suppes et al. 1991).
The primary therapeutic objective of maintenance
therapy is to prevent relapse and recurrence of acute
mood events, but as patients are likely to receive
maintenance treatment for extensive periods of time,
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the tolerability of these agents is also an important
consideration. A variety of guidelines exist for bipolar
disorders, covering both management of acute mood
episodes and long-term prophylaxis (APA, 2002;
Goodwin, 2003 ; Grunze et al. 2010; International
Consensus Group, 2008; NICE, 2006; Scottish Inter-
collegiate Guidelines Network, 2005 ; Suppes et al.
2005; Yatham et al. 2009). The majority of guidelines
include lithium in their recommendations for ﬁrst-line
maintenance therapy (APA, 2002; Goodwin, 2003;
NICE, 2006; Scottish Intercollegiate Guidelines Net-
work, 2005 ; Yatham et al. 2009). Recommendations
for other ﬁrst-line maintenance therapies vary, but
usually include divalproex or lamotrigine, and some-
times olanzapine (Fountoulakis et al. 2005). In contrast
to most guidelines, those provided by the Texas Im-
plementation of Medication Algorithms recommend
diﬀerent approaches to bipolar maintenance treat-
ment, depending on the nature of the preceding
acute episode (Suppes et al. 2005). After an episode of
mania or hypomania, lithium or divalproex are rec-
ommended, whereas following an acute episode of
depression, lamotrigine is recommended, either as
monotherapy or in combination with an antimanic
agent such as lithium or divalproex (Suppes et al. 2005).
It is likely that there are many reasons underlying
the variations in guidelines, including the paucity
of controlled head-to-head trials on which to base
recommendations, diﬀerences in the availability of
pharmacological products, and diﬀerences in personal
experiences and opinions. Furthermore, variation may
reﬂect the rapidly changing armamentarium of agents
available for bipolar maintenance, which can result in
guidelines becoming outdated (Vieta et al. 2005).
Guidelines that are frequently updated, or that have
been recently updated, will be based upon diﬀerent
data than those for which an update is due.
In the absence of randomized head-to-head clinical
trials of available therapies, physicians, healthcare
providers, and organizations involved in drafting
guidelines must rely on comparative data obtained
from systematic reviews and meta-analyses when
making treatment decisions and recommendations. A
number of such analyses have been conducted on
maintenance therapies for bipolar disorders (Bowden
et al. 2000a ; Chou & Fazzio, 2006 ; Derry & Moore,
2007 ; Grunze et al. 2004; Hellewell, 2006 ; Muzina &
Calabrese, 2005 ; Rybakowski, 2005 ; Sachs & Thase,
2000 ; Smith et al. 2007). In the past, these analyses have
provided useful information regarding the appropri-
ate maintenance treatment for bipolar disorder ; how-
ever, some analyses have included only selected drug
classes, which limits interpretation of the ﬁndings in
the context of available therapies (Bowden et al.
2000a ; Derry & Moore, 2007 ; Grunze et al. 2004;
Hellewell, 2006 ; Muzina & Calabrese, 2005;
Rybakowski, 2005 ; Sachs & Thase, 2000). Moreover,
with the introduction of new therapies and publi-
cations of new trials of existing therapies, these
analyses now need updating.
The most recently published comprehensive analy-
sis on maintenance therapies was conducted by Smith
et al. (2007) ; however, the cut-oﬀ date for inclusion
was March 2005. Since this time, there have been many
developments in the ﬁeld of bipolar disorder, includ-
ing new placebo-controlled trials assessing not only
traditional maintenance therapies, such as lithium, but
also newer options such as aripiprazole, long-acting
risperidone, olanzapine, oxcarbazepine, quetiapine
and ziprasidone. The introduction of new therapies for
bipolar disorder – with diﬀerent mechanisms of action
and indications for both acute and maintenance treat-
ment – raises questions about its optimal manage-
ment. For example : Is there a rationale for distin-
guishing between drugs with diﬀerent mechanisms
of action as maintenance treatment options? Do any
drugs show eﬃcacy against the recurrence of manic/
mixed and depressed mood events (that is to say at
both poles of bipolar illness)?
The objective of the current analysis was to deter-
mine the relative eﬃcacy of pharmacological therapy
in the maintenance treatment of bipolar disorder using
evidence from independent clinical trials. In addition,
we also consider the ﬁndings in the context of the
questions outlined above.
Methods
Population
The intended analysis population consisted of adults
(aged o18 yr) with a diagnosis of bipolar disorder.
Both monotherapies and combination therapies, used
as bipolar maintenance or relapse/recurrence pre-
vention, were included in the meta-analysis.
Data sources
We searched Medline (1993 to May 2010), EMBASE
(1993 to May 2010) and the Cochrane Library. We
supplemented this by searching reference lists of
identiﬁed trials and reviews. The language of publi-
cation was restricted to English. In the ﬁrst instance we
used the search term: bipolar AND (maintenance OR
prophylaxis OR prevention OR preventive OR recurrence
OR relapse) AND randomized AND trial. To capture ad-
ditional maintenance trials with bipolar mania and
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related symptoms as index (initial) episode the fol-
lowing search string was also used: bipolar AND
(mania OR manic OR cyclothymic OR hypomania OR
rapid cycling) AND randomized AND trial. Diﬀerent
variants and spellings were tested whenever relevant.
A sequential search procedure was used. The ﬁrst
step was a search that combined typical key words for
the indication and clinical trials. As a second step, the
indication was combined with individual drug names:
carbamazepine, valproate/divalproex/valproic acid,
clonazepam, phenytoin, oxcarbazepine, licarbazepine,
eslicarbazepine, gabapentin, levetiracetam, pregaba-
lin, tiagabine, lamotrigine, topiramate, zonisamide,
and retigabine, amisulpride, aripiprazole, clozapine,
olanzapine, olanzapine+ﬂuoxetine, quetiapine im-
mediate release (IR) and extended release (XR),
risperidone, risperidone injection (long-acting), halo-
peridol, chlorpromazine, pimozide, perphenazine,
ﬂupent(h)ixol, ziprasidone, asenapine, paliperidone,
bifeprunox, lurasidone and zotepine. Antidepress-
ants : paroxetine, ﬂuoxetine, sertraline, citalopram,
escitalopram, bupropion, venlafaxine, duloxetine,
desvenlafaxine, imipramine, moclobemide, mirtaza-
pine, tranylcypromine and agomelatine. Other : pra-
mipexole, modaﬁnil, inositol, tamoxifen and omega-3
fatty acids.
Eligibility criteria comprised: double-blind con-
trolled studies (having either a placebo or active com-
parator), a duration of at least 6 months, and a
minimum of 15 patients per treatment arm. These
duration and sample sizes are recommended by
regulatory agencies or required for conformational
statistical testing.
Data extraction and outcomes
Two reviewers decided whether individual studies
met the inclusion criteria. A standardized form, which
included patient and study characteristics, outcome
measures, and study results, was used to indepen-
dently extract data from the selected studies. Data
from intention-to-treat analyses (where available) and
outcome data at the longest available follow-up were
analysed.
Results are presented for relative risk (RR) of re-
lapse for patients in remission and all-cause discon-
tinuation during the randomized phase.
Data synthesis
The outcomes were combined in a meta-analysis.
Binary outcomes (RR) were pooled by risk ratios using
the Mantel–Haenszel method (Sutton et al. 2000).
Heterogeneity between studies was measured with
the x2 test and the I2 score. The I2 score measures the
proportion of heterogeneity in individual studies that
cannot be explained by chance (Higgins & Thompson,
2002 ; Higgins et al. 2003). It ranges between 0% and
100%, with lower values representing less heterogen-
eity. A high value reﬂects genuine diﬀerences between
the results of the studies, while a low value reﬂects
diﬀerences compatible with chance alone (Higgins
et al. 2003). If the x2 test indicated heterogeneity,
the random-eﬀects analysis was performed using
DerSimonian and Laird methods (DerSimonian &
Laird, 1986).
Statistical software
All calculations were performed with the general
purpose statistical software package Stata version 10.2
(StataCorp LP, USA). The METAN package of Stata was
used for performing the meta-analyses.
Results
After screening, 226 publications were identiﬁed
through the combined search strategies, and we
identiﬁed 21 trials, with a combined total of 5364 par-
ticipants that fulﬁlled the inclusion criteria (Bowden
et al. 2000b, 2003, 2010; Calabrese et al. 2000, 2003,
2005 ; Greil et al. 1997; Hartong et al. 2003; Keck et al.
2007; Macfadden et al. 2009; McElroy et al. 2008;
Quiroz et al. 2010; Suppes et al. 2009; Tohen et al. 2003,
2004, 2005, 2006 ; Vieta et al. 2008a, b ; Young et al. 2008;
Zarate & Tohen, 2004). Table 1 shows details of all
trials included in the analysis.
We identiﬁed: one trial each for aripiprazole
(Keck et al. 2007), olanzapine+mood stabilizer (Tohen
et al. 2004), oxcarbazepine+lithium (Vieta et al. 2008a),
perphenazine+mood stabilizer (Zarate & Tohen,
2004), risperidone long-acting injectable monotherapy
(Quiroz et al. 2010), risperidone long-acting in-
jectable+mood stabilizer (Macfadden et al. 2009) and
ziprasidone+mood stabilizer (Bowden et al. 2010) ;
two trials for carbamazepine (Greil et al. 1997; Hartong
et al. 2003) and quetiapine+mood stabilizer (Suppes
et al. 2009; Vieta et al. 2008b) and quetiapine mono-
therapy (McElroy et al. 2008; Young et al. 2008) ; three
trials each for divalproex (Bowden et al. 2000a, b ; Greil
et al. 1997; Tohen et al. 2003), lamotrigine (Bowden et al.
2003; Calabrese et al. 2000, 2003) and olanzapine
(Tohen et al. 2003, 2005, 2006) ; and eight trials for
lithium (Bowden et al. 2000b, 2003 ; Calabrese et al.
2003, 2005 ; Greil et al. 1997; Hartong et al. 2003; Tohen
et al. 2005; Vieta et al. 2008a).
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Table 1. Characteristics of included studiesa
Study Treatment Patient population
Duration
(wk) Deﬁnition of relapse
Outcomes relating
to relapse/recurrenceb Discontinuationb
Bowden et al.
(2000b)
Following stabilization :
(1) DVP to give
71–125 mg/ml for
divalproex, n=187
(2) lithium to give
0.8–1.2 mmol/l, n=91
(3) placebo, n=94
Bipolar I disorder
At randomization :
Age : 39¡12 yr
Male : 49%
MRS : 3.4
52 Occurrence of a manic episode (MRS
score o16 or requiring hospitalization)
or depressive episode (requiring
antidepressant use or premature
discontinuation from the study due
to symptoms)
Any mood episode :
(1) 45/187 (24%)
(2) 28/91 (31%)
(3) 36/94 (38%)
Manic relapse :
(1) 33/187 (18%)
(2) 19/91 (21%)
(3) 21/94 (22%)
Depressive relapse :
(1) 12/187 (6%)
(2) 9/91 (10%)
(3) 15/94 (16%)
(1) All : 116/187, Relapse :
45/187, Intolerance/
non-compliance : 41/
187, Other : 30/187
(2) All : 69/91, Relapse :
28/91, Intolerance/
non-compliance :
32/91, Other : 9/91
(3) All : 71/94, Relapse :
36/94, Intolerance/
non-compliance :
11/94, Other : 24/94
Bowden et al.
(2003)
Following stabilization :
(1) lamotrigine
100–400 mg/d, n=59
(2) lithium to give 0.8–1.1
mEq/l, n=46
(3) placebo, n=70
Bipolar I disorder,
manic or hypomanic
At randomization :
Age : 41¡12 yr
Male : 47%
HAMD 17 : 7, CGI-S :
4.3,
MRS : 22
76 Requiring intervention – either
pharmacotherapy or electroconvulsive
therapy
Any mood episode :
(1) 28/58 (48%)
(2) 18/44 (41%)
(3) 49/69 (71%)
Manic relapse :
(1) 20/58 (34%)
(2) 8/44 (18%)
(3) 28/69 (41%)
Depressive relapse :
(1) 8/58 (14%)
(2) 10/44 (23%)
(3) 21/69 (30%)
(1) All : 56/59, Relapse :
28/59, Adverse event :
3/59
(2) All : 45/46, Relapse :
18/46, Adverse event :
11/46
(3) All : 70/70, Relapse :
49/70, Adverse event :
3/70
Bowden et al.
(2010)
Following stabilization :
(1) ziprasidone
80–160 mg/d
+lithium/divalproex
(to give 0.6–1.2 mEq/l
and 50–125 mg/ml,
respectively), n=127
(2) placebo+lithium/
divalproex (to give
0.6–1.2 mEq/l and
50–125 mg/ml,
respectively), n=113
Bipolar I disorder
At randomization :
Age : 39¡12 yr
Male : 46%
26 Investigator decision that
discontinuation was in best interests of
the subject, loss of eﬀect/requirement
of treatment change, hospitalization,
MRS o18 or MADRS o18 for 2
consecutive visits (<10 days apart)
Any mood episode :
(1) 25/127 (20%)
(2) 36/111 (32%)
Manic relapse :
(1) 9/127 (7%)
(2) 20/111 (18%)
Depressive relapse :
(1) 16/127 (13%)
(2) 16/111 (14%)
(1) All : 43/127, Lack of
eﬃcacy : 9/127,
Adverse event : 11/127
(2) All : 58/113, Lack of
eﬃcacy : 22/113,
Adverse event : 15/113
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Calabrese et al.
(2000)
Following stabilization :
(1) lamotrigine
100–500 mg/d, n=93
(2) placebo, n=89
Rapid cycling bipolar
disorder, manic,
mixed or depressed
At randomization :
Age : 38 yr
Male : 43%
HAMD 17 : 6, CGI-S :
2.1,
YMRS : 2.7
26 Requiring intervention for a mood
episode, or one that was emerging
Any mood relapse
(1) 53/90 (59%)
(2) 64/87 (74%)
(1) All : 56/93 Requiring
therapy : 45/93,
Adverse event : 1/93
(2) All : 66/89, Requiring
therapy : 49/89,
Adverse event : 2/89
Calabrese et al.
(2003)
Following stabilization :
(1) lamotrigine 50, 200 or
400 mg/d, n=221
(2) lithium to give 0.8–1.1
mEq/l, n=121
(3) placebo, n=121
Bipolar I disorder,
currently or recently
depressed
At randomization :
Age : 44¡12 yr
Male : 44%
HAMD 17 : 6, CGI-S :
2.0, MRS : 1.5
76 Requiring intervention for amood episode Any mood episode
(1) 115/215 (53%)
(2) 56/120 (47%)
(3) 66/119 (55%)
Manic relapse :
(1) 38/215 (18%)
(2) 10/120 (8%)
(3) 19/119 (16%)
Depressive relapse :
(1) 77/215 (36%)
(2) 46/120 (38%)
(3) 47/119 (39%)
(1) All : 183/221, Relapse :
115/221, Adverse
event : 20/221
(2) All : 101/121, Relapse :
56/121, Adverse
event : 19/121
(3) All : 109/121, Relapse :
66/121, Adverse
event : 12/121
Calabrese et al.
(2005)
Following stabilization :
(1) lithium >0.8 mEq/l,
n=32
(2) divalproex>50 mg/ml,
n=28
Bipolar I and II disorder
At randomization :
Age : 37¡9 yr
Male : 48%
Depressed : 60%
Hypomanic : 30%
Baseline HAMD: 21,
YMRS : 12
80 Requiring intervention for a mood
episode, or one that was emerging
Median time (wk) to intervention
for mood episode :
(1) 18
(2) 45 (diﬀerence not signiﬁcant)
Median time (wk) to discontinuation
for any reason
(1) 14
(2) 26 (diﬀerence not signiﬁcant)
(1) All : 27/32, Relapse :
18/32, Adverse event :
5/32
(2) All : 20/28, Relapse :
14/28, Adverse event :
1/28
Greil et al.
(1997)
Following stabilization :
(1) lithium to give
0.6–0.8 mmol/l, n=74
(2) carbamazepine to give
4–12 mg/ml, n=70
Bipolar I, At
randomization :
Age : 44¡14 yr
Males : 48%
GAS : 80
130 Research Diagnostic Criteria score of
5 or 6
Symptom recurrence of any
mood episode
(1) 17/60 (28%)
(2) 20/43 (47%)
(1) All : 14/74, Relapse :
17/60, Adverse event :
4/74
(2) All : 27/70, Relapse :
20/43, Adverse event :
9/70
Hartong et al.
(2003)
From a population of stable
patients :
(1) lithium to give
0.6–1.0 mmol/l, n=44
(2) carbamazepine to give
4–12 mg/ml, n=50
Bipolar I and II disorder
(BP I : 78%)
At randomization :
Age : 42¡14 yr
Males : 46%
BPRS : 1.8
104 Fulﬁlling DSM-III-R criteria for
(hypo)mania or major depression
Any mood relapse
(1) 12/44 (27%)
(2) 21/50 (19%)
(1) All : 16/44, Adverse
event : 5/44
(2) All : 13/50, Adverse
event : 4/50
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Table 1 (cont.)
Study Treatment Patient population
Duration
(wk) Deﬁnition of relapse
Outcomes relating
to relapse/recurrenceb Discontinuationb
Keck et al.
(2007)
Following stabilization :
(1) aripiprazole
15–30 mg/d, n=78
(39 at week 26)
(2) placebo, n=83 (27 at
week 26)
Bipolar I disorder
At randomization :
Age : 40¡1 yr
Male : 33%
Manic : 70%
Mixed : 30%
MADRS : 4,
YMRS : 2.3
100 Hospital admission due to a mood
episode and/or addition to or increase
in psychotropic medication for manic
and/or depressive symptoms
From week 6–100 :
Any mood episode :
(1) 25/77 (32%)
(2) 43/83 (52%)
Manic relapse :
(1) 9/77 (12%)
(2) 23/83 (28%)
Depressive relapse :
(1) 11/77 (14%)
(2) 13/83 (16%)
Mixed relapse :
(1) 4/77 (5%)
(2) 5/83 (6%)
Unknown relapse :
(1) 1/77 (1%)
(2) 2/83 (2%)
(1) All : 32/39, IR : 5/39,
Adverse event : 1/39
(2) All : 22/27, IR : 7/27,
Adverse event : 0/27
McElroy et al.
(2008)
Following stabilization :
(1) quetiapine 300 mg,
n=61
(2) quetiapine 600 mg,
n=66
(3) placebo, n=129
Bipolar I and II
disorder, following
treatment for acute
depressive episode
At randomization :
Age : 39 yr
Male : 37%
Bipolar I : 64%
52 Requiring medication to treat mood
episode, hospitalization for mood
episode, YMRS score o16 or MADRS
score o20, or discontinuation due to
mood episode
Hazard ratio for the time to
recurrence of a mood event of
0.43 (95% CI 0.27 to 0.69)
Hazard ratio for the time to
recurrence of a depressive event
of 0.36 (95% CI 0.21 to 0.63)
(1) All : 32/61
(2) All : 35/66
(3) All : 37/60
(4) All : 27/50
Macfadden
et al. (2009)
Following stabilization :
(1) risperidone long-acting
injectable 25–50 mg+
mood stabilizer, n=65
(2) mood stabilizer, n=59
Bipolar patients with
frequently relapsing
bipolar disorder
At randomization :
Age : 39¡12 yr
Male : 72%
52 DSM-IV-TR criteria for an acute mood
episode ; requiring additional
treatment and YMRS or MADRS >15
and CGI-S o4 or CGI-C o6 or GAF
reduction of >10 points ;
hospitalization for worsening of
symptoms or suicidal ideation
Any mood relapse :
(1) 15/65 (23%)
(2) 27/59 (46%)
Manic relapse :
(1) 5/65 (8%)
(2) 12/59 (20%)
Depressive relapse :
(1) 8/65 (12%)
(2) 11/59 (19%)
Mixed :
(1) 2/65 (3%)
(2) 4/59 (7%)
(1) All : 26/65, Relapse :
13/65, Adverse event :
3/65
(2) All : 34/59, Relapse :
23/59, Adverse event :
1/59
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Quiroz et al.
(2010)
Following stabilization :
(1) risperidone long-acting
injectable 12.5–50 mg,
n=154
(2) placebo, n=149
Bipolar I disorder
At randomization :
Age : 39¡12 yr
Male : 51%
Manic : 79%
Mixed : 21%
MADRS : 1.9
YMRS : 2.4
CGI-S : 1.6
104 DSM-IV-TR criteria for a
manic, hypomanic, mixed, or
depressive episode ; treatment
intervention ; hospitalization ; YMRS
score >12, MADRS score >12, or
CGI-S score >4 at any visit ; or needing
additional risperidone
Any mood episode :
(1) 42/135 (31%)
(2) 76/133 (57%)
Manic relapse :
(1) 22/135 (16%)
(2) 62/133 (47%)
Depressive relapse :
(1) 20/135 (15%)
(2) 14/133 (11%)
(1) All : 40/154, Adverse
events : 15/154
(2) All : 37/149, Adverse
events : 33/149
Suppes et al.
(2009)
Following stabilization :
(1) quetiapine
400–800 mg/d
+lithium/divalproex
(to give 0.5–1.2 mEq/l
and 50–125 mg/ml,
respectively), n=310
(2) placebo+lithium/
divalproex, n=313
Bipolar I disorder with
o1 episode of mania,
depression, or a mixed
episode in last 2 yr
At randomization :
Age : 40¡12 yr
Male : 48%
Manic : 24%
Depressed : 31%
Mixed : 46%
MADRS : 4.8, YMRS : 3.6
104 Requiring treatment for mixed, manic, or
depressive symptoms, hospitalization,
YMRS or MADRS total scores o20 at
two consecutive assessments ;
or discontinuation because of a
mood event
Hazard ratio for the time to recurrence
of a mood event of 0.32 (p<0.0001),
corresponding to a risk reduction of
68% for quetiapine+lithium/
divalproex compared to placebo+
lithium/divalproex
Hazard ratio for the time to recurrence
of a mania event of 0.30 (p<0.0001),
corresponding to a risk reduction of
70%
Hazard ratio for the time to recurrence
of a depressive event of 0.33
(p<0.0001), corresponding to a risk
reduction of 67%
(1) All : n.a., Relapse :
63/310, Adverse
event : 23/310
(2) All : n.a., Relapse :
163/313, Adverse
event : 8/313
Tohen et al.
(2003)
(1) olanzapine 5–20 mg/d,
n=125
(2) divalproex
500–2500mg/d, n=126
Bipolar disorder, manic
or mixed
Age : 41 yr
Male : 43%
Manic : 57%
Mixed : 43%
HAMD:14, YMRS : 28
47 YMRS or HAMD o15 YMRS f12
(1) 71/125 (57%)
(2) 57/126 (45%)
Median time to remission (days)
(1) 14
(2) 62
YMRS f12 and MADRS f8 at 47 wk
(1) 39/125 (31%)
(2) 39/126 (31%)
Symptomatic relapse into aﬀective
episode (YMRS o15 or HAMD o15)
(1) 14/33 (42%)
(2) 13/23 (57%)
(1) All : 106/125, IR :
24/125, Adverse
event : 31/125
(2) All : 106/126, IR :
28/126, Adverse
event : 25/126
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Table 1 (cont.)
Study Treatment Patient population
Duration
(wk) Deﬁnition of relapse
Outcomes relating
to relapse/recurrenceb Discontinuationb
Tohen et al.
(2004)
Following stabilization :
(1) olanzapine 5–20 mg/d
+lithium (0.6–
1.2 mmol/l) or
divalproex, n=51
(2) placebo+lithium
(0.6–1.2 mmol/l) or
divalproex, n=48
Bipolar I disorder with
remission of manic
episode after
treatment with
olanzapine+
lithium or divalproex
At randomization :
Age : 41 yr
Male : 48%
Manic : 50%
Mixed : 50%
78 DSM-IV criteria for a manic mixed
or depressive episode, or
symptomatic according to the YMRS
or HAMD
Symptomatic relapse into aﬀective
episode (YMRS +/or HAMDo15)
without symptoms initially
(1) 11/30 (37%)
(2) 21/38 (55%)
Median time to relapse (days)
(1) 163
(2) 42
Depression alone :
(1) 7/30–23% (163 days)
(2) 15/38–39% (55 days)
Mania alone :
(1) 6/30–20% (172 days)
(2) 11/38–29% (59 days)
(1) All : 35/51, IR : 13/51,
Adverse event : 5/51
(2) All : 43/48, IR : 17/48,
Adverse event : 8/48
Tohen et al.
(2005)
Following stabilization :
(1) olanzapine 5–20 mg/d,
n=217
(2) lithium to give
0.6–1.2 mEq/l, n=214
Bipolar disorder
At randomization :
Age : 42¡13 yr
Male : 47%
Manic : 93%
Psychotic : 26%
Baseline HAMD: 3.8,
YMRS : 1.6
52 YMRS or HAMD o15 Symptomatic recurrence of any mood
episode (YMRS +/or HAMD o15)
(1) 65/217 (30%)
(2) 83/214 (39%)
Mania :
(1) 30/217 (14%)
(2) 50/214 (23%)
Depression :
(1) 34/217 (16%)
(2) 23/214 (11%)
Time to recurrence not
signiﬁcantly diﬀerent between groups
(1) All : 116/217, IR : 31/
217, Adverse event :
41/217
(2) All : 144/214, IR : 34/
214, Adverse event :
55/214
1036
E
.
V
ieta
et
al.
Tohen et al.
(2006)
Following stabilization :
(1) olanzapine 5–20 mg/d,
n=225
(2) placebo, n=136
Bipolar I disorder
At randomization :
Age : 40¡12 yr
Male : 39%
Manic : 66%
Mixed : 34%
Psychotic : 18%
HAMD: 3.6, YMRS : 4.2
48 YMRS or HAMD o15 or hospitalization
for a manic, mixed or depressive
episode
Symptomatic recurrence of
any mood episode
(1) 105/225 (47%)
(2) 109/136 (80%)
Mania :
(1) 27/225 (12%)
(2) 44/136 (32%)
Depression :
(1) 68/225 (30%)
(2) 53/136 (39%)
Mixed :
(1) 10/225 (4%)
(2) 12/136 (9%)
Time to any relapse :
(1) 174 days
(2) 22 days
(1) All : 72/225, IR : 4/225,
Adverse event : 17/225
(2) All : 18/136, IR : 2/136,
Adverse event : 0/136
Vieta et al.
(2008a)
(1) oxcarbazepine
1200 mg/d+lithium,
n=26
(2) placebo+lithium, n=29
Bipolar I and II patients
currently in remission
Age : 44 yr
Male : 35%
52 DSM-IV-TR criteria for a manic,
hypomanic, mixed or depressive
episode, YMRS >12 or MADRS >20
Manic relapse :
(1) 4/26 (15%)
(2) 8/29 (28%)
Depressive relapse :
(1) 3/26 (12%)
(2) 9/29 (31%)
Mixed relapse :
(1) 1/26 (4%)
(2) 1/29 (3%)
Any mood episode :
(1) 8/26 (31%)
(2) 18/29 (62%)
(1) All : 10/26, Adverse
event : 3/26
(2) All : 10/29, Adverse
event : 2/29
Vieta et al.
(2008b)
Following stabilization :
(1) quetiapine
400–800 mg/d
+lithium/divalproex
(to give 0.5–1.2 mEq/l
and 50–125 mg/ml),
n=336
(2) placebo+lithium/
divalproex, n=367
Bipolar I disorder with
current or recent
mixed, manic, or
depressed episode
At randomization :
Age : 42¡13 yr
Male : 45%
Manic : 48%
Depressed : 29%
Mixed : 23%
MADRS: 3.5, YMRS: 2.4
104 YMRS or MADRS o20 at two
consecutive assessments or
discontinuation due to an event
(mania, depression or mixed), or
hospitalization for mania, depression
or a mixed event ; or intervention to treat
mania, depression or a
mixed event
Hazard ratio for the time to recurrence
of a mood event of 0.28 (p<0.001),
corresponding to a risk reduction of
72% for quetiapine+lithium/
divalproex compared to placebo+
lithium/divalproex
Hazard ratio for the time to recurrence
of a mania event of 0.30 (p<0.001),
corresponding to a risk reduction
of 70%
Hazard ratio for the time to recurrence
of a depressive event of 0.26 (p<0.001),
corresponding to a risk reduction
of 74%
(1) All : 123/336, Relapse :
62/336, Adverse
event : 8/336
(2) All : 233/367, Relapse :
180/367, Adverse
event : 9/367
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Table 1 (cont.)
Study Treatment Patient population
Duration
(wk) Deﬁnition of relapse
Outcomes relating
to relapse/recurrenceb Discontinuationb
Young et al.
(2008)
Following stabilization :
(1) quetiapine 300 mg,
n=80
(2) quetiapine 600 mg,
n=83
(3) placebo, n=165
Bipolar I and II
disorder, following
treatment for acute
depressive episode
At randomization :
Age : 41 yr
Male : 41%
Bipolar I : 62%
52 Hazard ratio for the time to recurrence
of a mood event of 0.56 (95% CI
0.39–0.82)
Hazard ratio for the time to recurrence
of a depressive event of 0.48 (95%
CI 0.29–0.77)
(1) All : 37/80
(2) All : 36/84
(3) All : 24/63
(4) All : 36/74
Zarate &
Tohen (2004)
Following stabilization
(1) perphenazine
4–64 mg/d+mood
stabilizer/s, n=18
(2) placebo+mood
stabilizer/s, n=19
Bipolar I disorder.
Maintenance after
stabilization of manic/
mixed episode
(1) Age : 36 yr, Male :
24%,
(2) manic : 65%, mixed :
35%
26 DSM-IV criteria for a manic
or depressive episode
Manic relapse :
(1) 1/19 (5%)
(2) 2/18 (11%)
Depressive relapse :
(1) 4/19 (21%)
(2) 0/18 (0%)
Any mood episode :
(1) 5/19 (26%)
(2) 2/18 (11%)
(1) All : 10/19, Adverse
event : 4/19
(2) All : 3/18, Adverse
event : 1/18
BPRS, Brief Psychiatric Rating Scale ; CGI-S, Clinical Global Impression – Severity ; CGI-C, Clinical Global Impression – Change ; CI, conﬁdence interval ; GAF, global assessment of
functioning ; HAMD, Hamilton Rating Scale for Depression ; IR, insuﬃcient response ; MADRS, Montgomery–A˚sberg Depression Rating Scale ; MRS, Mania Rating Scale ; TEM,
treatment-emergent mania ; YMRS, Young Mania Rating Scale.
aWhile every eﬀort has been made to provide consistent data, variations in individual publications precluded the ability to provide consistency across all studies.
b Diﬀerences in total patient numbers between the outcomes and discontinuations columns reﬂects diﬀerences in datasets. In general, the intention-to-treat population is used to
calculate discontinuations, whereas the eﬃcacy datasets include only patients who received at least one dose of medication.
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The length of follow-up was 26 wk in three studies
(Bowden et al. 2010; Calabrese et al. 2000; Zarate &
Tohen, 2004), between 47 and 52 wk in eight studies
(Bowden et al. 2000b ; Macfadden et al. 2009; McElroy
et al. 2008; Tohen et al. 2003, 2005, 2006 ; Vieta et al.
2008a ; Young et al. 2008), between 72 and 80 wk in
four studies (Bowden et al. 2003; Calabrese et al. 2003,
2005 ; Tohen et al. 2004) and between 100 and 130 wk in
six studies (Greil et al. 1997; Hartong et al. 2003; Keck
et al. 2007; Quiroz et al. 2010; Suppes et al. 2009; Vieta
et al. 2008b). Median follow-up among the 21 studies
was 52 wk, and mean follow-up was 68 wk. The
majority of studies included a ‘stabilization phase’
during which patients received treatment for an acute
episode, and only those patients who responded to
treatment were permitted to continue in the mainten-
ance analysis. The index episodes in the acute treat-
ment phases diﬀered for individual studies, which
may have inﬂuenced the ﬁndings (Table 2).
A number of studies were excluded from the meta-
analytical calculations because they did not include
a placebo group, and used diﬀerent comparators
(Calabrese et al. 2005; Greil et al. 1997; Hartong et al.
2003; Tohen et al. 2003, 2005).
Eﬃcacy relative to comparator
RR for relapse of any mood episode
The combined evidence for both manic and depressive
relapses is shown in Figs 1a and 1b. All monotherapies
had RRs signiﬁcantly diﬀerent from 1.0, favouring
treatment. The overall estimate of the RR of any mood
episode relapse compared to comparator (placebo)
was 0.68 [95% conﬁdence interval (CI) 0.60–0.77,
p<0.001], which is of the same order of magnitude as
the overall RR for the individual events in mainten-
ance treatment (shown below). The heterogeneity was
moderate with an I2 score of 52.3%.
Among the combination therapies, oxcarbazepine+
lithium, quetiapine+lithium/divalproex, risper-
idone+mood stabilizer, and ziprasidone+lithium/
divalproex had RRs signiﬁcantly diﬀerent from 1.0,
favouring treatment. The overall estimate of the RR of
any mood relapse for combination therapy compared
to comparator [lithium (Vieta et al. 2008a) ; lithium/
divalproex (Bowden et al. 2010; Suppes et al. 2009;
Tohen et al. 2004; Vieta et al. 2008b) ; mood stabilizer
(Macfadden et al. 2009; Zarate & Tohen, 2004)] was
0.49 (95% CI 0.39–0.61, p<0.001). The heterogeneity
was moderate with an I2 score of 50.3%. The point
estimate for quetiapine+lithium/divalproex was the
lowest with a RR of 0.38 (95% CI 0.32–0.46).
Quetiapine, however, represented a large part of the
evidence for the RR of mood relapse in bipolar main-
tenance with 47% of the weight in the overall estimate
for combination therapy.
RR for manic/mixed relapse
All of the therapies – both monotherapy and combi-
nation – were found to have a RR for manic/mixed
Table 2. Index episodes for maintenance studies
Authors Year Interventions Index episode/s
Calabrese et al. 2003 LTG/Li/Placebo Depressive episode
McElroy et al. 2008 QTP 300/QTP 600/Placebo Depressive episode
Young et al. 2008 QTP 300/QTP 600/Placebo Depressive episode
Calabrese et al. 2000 LTG/Placebo Manic, mixed, or depressive episode
Vieta et al. 2008b QTP+Li or DVP/Placebo+Li or DVP Manic, mixed, or depressive episode
Suppes et al. 2009 QTP+Li or DVP/Placebo+Li or DVP Manic, mixed, or depressive episode
Bowden et al. 2000b DVP/Li/Placebo Manic/mixed episode
Zarate et al. 2004 PPZ+Li or DVP/Placebo+Li or DVP Manic/mixed episode
Tohen et al. 2004 OLZ+Li or DVP/Placebo+Li or DVP Manic/mixed episode
Tohen et al. 2006 OLZ/Placebo Manic/mixed episode
Keck et al. 2007 ARP/Placebo Manic/mixed episode
Bowden et al. 2010 ZIP+ Li or DVP/Placebo+Li or DVP Manic/mixed episode
Bowden et al. 2003 LTG/Li/Placebo Manic/hypomanic episode
Vieta et al. 2008a OXC+Li/Placebo+Li In remission at inclusion
ARP, Aripiprazole ; DVP, divalproex; Li, lithium; LTG, lamotrigine ; OLZ, olanzapine ; OXC, oxcarbazepine ; QTP, quetiapine ;
PPZ, perphenazine ; ZIP, ziprasidone.
Studies without placebo comparator were excluded from the analysis (Calabrese et al. 2005 ; Greil et al. 1997 ; Hartong et al. 2003 ;
Tohen et al. 2003, 2005).
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relapse that was below 1.0, although signiﬁcance vs.
placebo or comparator varied among treatments
(Figs 2a, 2b). The magnitude of the reduction in risk
vs. placebo also varied between studies. Divalproex,
lamotrigine, lithium and quetiapine monotherapy
all had CIs extending beyond 1.0. The point estimate
in one of the two studies concerning lamotrigine
was below 1.0 (Calabrese et al. 2003), but both studies
had quite wide CIs with the upper conﬁdence limit
for the RR being above 1.0 (Bowden et al. 2003;
Calabrese et al. 2003). A similar ﬁnding was observed
for 300 mg quetiapine, with one point estimate
below 1.0 (McElroy et al. 2008) and the other above
1.0 (Young et al. 2008). As with lamotrigine, both
studies had quite wide CIs with the upper conﬁdence
limit for the RR being above 1.0 (McElroy et al.
2008; Young et al. 2008). The overall estimate of the
RR of manic/mixed relapse compared to placebo
was 0.65 (95% CI 0.51–0.84) for monotherapy
(p=0.001). The heterogeneity was moderate with an I2
score of 56.6%.
Of the combination treatments, only quetiapine+
lithium/divalproex, long-acting risperidone+mood
stabilizer, and ziprasidone+lithium/divalproex had
RRs for manic/mixed relapse vs. their comparator
treatments (lithium/divalproex and mood stabilizer,
respectively) that were signiﬁcantly below 1.0 (RR
0.39, 95% CI 0.30–0.52, p<0.001; RR 0.40, 95% CI
0.18–0.90, p=0.026 ; RR 0.39, 95% CI 0.19–0.83,
p=0.014, respectively) (Fig. 2b). The overall estimate
of the RR of manic/mixed relapse compared to com-
parator [lithium (Vieta et al. 2008a) ; lithium/
divalproex (Bowden et al. 2010; Suppes et al. 2009;
Tohen et al. 2004; Vieta et al. 2008b) ; mood stabilizer
(Bowden et al. 2000b ; Zarate & Tohen, 2004)] was
0.42 (95% CI 0.33–0.53, p<0.001) for combination
Fig. 1a. Relative risk of any mood episode – monotherapies. Heterogeneity : 3, lamotrigine (I2=47.4%) ; 4, lithium (I2=25.7%) ;
6, quetiapine (I2=0.0%) ; 7, quetiapine (I2=31.0%) ; overall (I2=52.3%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence
interval ; ARP, aripiprazole ; DVP, divalproex ; Li, lithium; LTG, lamotrigine ; OLZ, olanzapine ; QTP, quetiapine ; RLAI,
risperidone long-acting injectable.
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therapy (Fig. 2b). The heterogeneity was low with an I2
score of 0% (scores lower than zero are assigned the
value zero).
RR for depressive relapse
The point estimates for all monotherapies except long-
acting injectable (LAI) risperidone were below 1.0 ;
however, only divalproex (p=0.013), and quetiapine
monotherapy (p=0.004 for 300 mg/d and p=0.002 for
600 mg/d) had RRs for relapse to a depressive episode
that were signiﬁcantly below 1.0 (Fig. 3a). The overall
estimate of the RR of depressive relapse for mono-
therapy compared to placebo was 0.70 (95% CI
0.58–0.85), which is of a similar order of magnitude as
the overall RR for manic/mixed relapse in mainten-
ance treatment. The heterogeneity was moderate with
an I2 score of 45.5%.
The overall estimate of the RR of depressive relapse
for combination therapy compared to comparator
[lithium (Vieta et al. 2008a) ; lithium/divalproex
(Suppes et al. 2009; Tohen et al. 2004; Vieta et al.
2008b) ; mood stabilizer (Macfadden et al. 2009; Zarate
& Tohen, 2004)] was 0.48 (95% CI 0.35–0.64, p<0.001)
(Fig. 3b). The heterogeneity was moderate with an I2
score of 35%. Only for quetiapine in combination with
lithium/divalproex was the RR signiﬁcantly below 1.0
compared to the comparator (p<0.001 and p=0.039,
respectively). Together with oxcarbazepine, which
had a mean RR of 0.37, the point estimate was also the
lowest with a RR of 0.38 (95% CI 0.29–0.49, p<0.001).
Quetiapine represented the major part of the evidence
for the RR of depressive relapse in bipolar mainten-
ance with 57% of the weight in the overall estimate for
combination therapy.
RR for all-cause discontinuation
The RRs of all-cause discontinuation during the ran-
domized phase in bipolar maintenance monotherapies
were signiﬁcantly lower than 1.0 for quetiapine,
lamotrigine and divalproex (Fig. 4a). The ﬁnding for
olanzapine monotherapy appeared to be an outlier,
with a RR of 2.42 (95% CI 1.51–3.87, p<0.001).
However, as this was only based on one study (Tohen
et al. 2006), this estimate is of questionable validity
given the results for olanzapine in combination with a
mood stabilizer, where the RR in the combination
therapy arm was 0.77 (95% CI 0.62–0.94, p=0.013)
compared to mood stabilizer alone (Fig. 4b) (Tohen
Fig. 1b. Relative risk of any mood episode – combination therapies. Heterogeneity : 4, quetiapine+Li/DVP (I2=0.0) ; overall
(I2=50.3%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence interval ; DVP, divalproex ; Li, lithium; OLZ, olanzapine ;
OXC, oxcarbazepine ; QTP, quetiapine ; PPZ, perphenazine ; RLAI, risperidone long-acting injectable ; ZIP, ziprasidone.
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et al. 2004). The olanzapine monotherapy ﬁnding is
primarily explained by the low rate of discontinuation
in the placebo arm (18/36=13%), rather than a
high discontinuation rate in the treatment group
(72/225=32%).
The overall estimate of the RR of discontinuation for
monotherapy compared to placebo was 0.93 (95% CI
0.87–0.99, p=0.024). The heterogeneity was moderate
with an I2 score of 64.0%. This means that it is very
unlikely that observed diﬀerences are due to chance
alone (Higgins et al. 2003).
The RRs of discontinuation in bipolar maintenance
combination therapies were signiﬁcantly lower than
1.0 for the olanzapine+lithium/divalproex, quetiapine+
lithium/divalproex and ziprasidone+lithium/dival-
proex combinations (Fig. 4b). Long-acting risperidone
in combination with a mood stabilizer had a RR
that was not signiﬁcantly below 1.0 (p=0.056) com-
pared to mood stabilizer alone, but the upper con-
ﬁdence limit was close to 1.0. Compared to mood
stabilizer, oxcarbazepine (RR 1.12) and perphenazine
(RR 3.16) combination therapies had a RR larger than
1.0 compared to mood stabilizer alone. Both studies
were quite small with sample sizes per arm ranging
from 18 in the control group of the perphenazine
study to 29 patients in the control group of the
oxcarbazepine study, but the CI for perphenazine still
did not encompass zero (95% CI 1.03–9.66). However,
the rate of discontinuation in the perphenazine arm
was not exceptionally high (10/19), rather, the dis-
continuation rate in the control arm (mood stabilizer
alone) was unusually low (3/18). Again, this may be
due to the small sample size.
The overall estimate of the RR of discontinuation
for combination therapy compared to mood
stabilizer was 0.75 (95% CI 0.62–0.90, p=0.003). The
Fig. 2a. Relative risk of manic or mixed relapse – monotherapies. Heterogeneity : 3, lamotrigine (I2=0.0%) ; 4, lithium
(I2=36.9%) ; 6, quetiapine (I2=0.0%) ; 7, quetiapine (I2=31.0%) ; overall (I2=56.6%). Dosages are in mg/d. RR, Relative risk ;
CI, conﬁdence interval ; ARP, aripiprazole ; DVP, divalproex ; LTG, lamotrigine ; Li, lithium; OLZ, olanzapine ; QTP, quetiapine ;
RLAI, risperidone long-acting injectable.
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heterogeneity was high with an I2 score of 73.1%.
Ziprasidone+lithium/divalproex combination ther-
apy had the lowest discontinuation (RR 0.66, 95% CI
0.49–0.89, p=0.007).
Discussion
This analysis identiﬁed considerable variation in eﬃ-
cacy among bipolar maintenance therapies. In general,
the RR of relapse to any mood event was more hom-
ogenous across the treatments investigated than if
manic/mixed or depressive events were considered
separately. All medications (mono- and combination
therapy) showed a RR for manic/mixed relapse that
was below 1.0, although signiﬁcance vs. placebo varied
among treatments. The risk for depressive relapse
was below 1.0 for all monotherapy studies identiﬁed
except for the risperidone LAI study, although
only divalproex and quetiapine showed signiﬁcance
vs. placebo. For the combination therapies, only
quetiapine+lithium/divalproex had a RR of depress-
ive relapse signiﬁcantly below 1.0. Interestingly, the
combination therapy quetiapine+lithium/divalproex
had a RR for both manic/mixed episode and
depressive relapse signiﬁcantly below 1.0, suggesting
that this intervention is eﬀective in preventing relapse
to either pole of bipolar illness.
Variation was also observed in the RRs for all-cause
discontinuations, with RRs signiﬁcantly lower than 1.0
for quetiapine monotherapy and combination therapy,
divalproex monotherapy, lamotrigine monotherapy,
olanzapine combination therapy, and ziprasidone
combination therapy. The small sample sizes for some
of the studies, however, may have contributed to the
higher RR of discontinuation for olanzapine mono-
therapy and the oxcarbazepine and perphenazine
combination therapies. Furthermore, as there may
be many diﬀerent reasons for discontinuations –
administrative reasons, tolerability problems, lack of
eﬃcacy or hidden relapses – caution is advised when
comparing discontinuation rates across studies.
Population enrichment may contribute to the vari-
ation observed between studies. Some studies, for
example, those conducted by Bowden et al. (2003),
Calabrese et al. (2000, 2003, 2005), Keck et al. (2007),
Suppes et al. (2009), Tohen et al. (2004, 2005, 2006) and
Fig. 2b. Relative risk of manic or mixed relapse – combination therapies. Heterogeneity : 4, quetiapine+Li/DVP (I2=0.0%) ;
overall (I2=0.0%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence interval ; DVP, divalproex ; Li, lithium; OLZ,
olanzapine ; OXC, oxcarbazepine ; PPZ, perphenazine ; QTP, quetiapine ; RLAI, risperidone long-acting injectable ; ZIP,
ziprasidone.
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Vieta et al. (2008b) incorporated a stabilization period
into the study design after which non-responsive
patients or those not considered clinically stable did
not participate further. This could be viewed as arti-
ﬁcial selection of the most responsive patients, which
would limit the comparability between studies. It
could also inﬂuence the rate of discontinuations as
discussed above. However, we did not ﬁnd any sig-
niﬁcant diﬀerences between the studies in terms of
the RR of relapse or discontinuation depending on
whether the trials included a stabilization phase or not.
The index episode resulting in the initial treatment also
diﬀered between studies. In some studies,maintenance
treatment was initiated after an acute manic or mixed
episode and in other studies after an acute depressive
episode. The polarity of the index episode has a rel-
evant impact on the power to prevent further episodes
of the same polarity (Calabrese et al. 2004). For instance,
the results for quetiapine showed a higher RR favour-
ing treatment for depressive relapse than for manic/
mixed relapse, while it was the other way around for
olanzapine. Hence, at least a partial explanation for this
is that the initial episodes were diﬀerent in the re-
spective studies, where all patients in the olanzapine
study had a manic/mixed index episode, while a sub-
stantial proportion of the patients in the quetiapine
studies had acute depression as index episode. The in-
dex episode may therefore be a potential source of
heterogeneity in the studies, and will aﬀect the results
concerning the relapse rates. Diﬀerences in placebo re-
sponse is an additional factor that may potentially lead
to bias in the results, but no signiﬁcant correlation
between the placebo response and the RR of a mood
episode was found (Spearman’s rank correlation coef-
ﬁcient=x0.051, p=0.836), indicating that the placebo
response and the RR are independent.
Fig. 3a. Relative risk of depressive relapse – monotherapies. Heterogeniety : 3, lamotrigine (I2=67.1%) ; 4, lithium (I2=19.4%) ;
6, quetiapine (I2=0.0%) ; 7, quetiapine (I2=21.9%) ; overall (I2=45.5%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence
interval ; ARP, aripiprazole ; DVP, divalproex ; LTG, lamotrigine ; Li, lithium; OLZ, olanzapine ; QTP, quetiapine ; RLAI,
risperidone long-acting injectable.
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The meta-analysis presented here was intended to
have a broader scope than some of the previously
published meta-analyses, including many studies that
had not been published when previous analyses
were carried out. However, despite this the number of
studies for some medications, e.g. aripiprazole, was
not large. In contrast, lithium was well represented in
these studies, reﬂecting its established position as a
maintenance therapy for bipolar disorder. Another
limitation of this analysis relates to the comparability
of the data from these studies. Diﬀerences exist in
the deﬁnition of a relapse, potentially making some
studies more sensitive than others to demonstrations
of eﬃcacy. For example, some studies deﬁned relapse
as initiation of treatment at the discretion of the treat-
ing physician (e.g. Bowden et al. 2003; Calabrese et al.
2000, 2003), some studies included hospitalization in
their criteria for relapse (e.g. Bowden et al. 2000b ;
Greil et al. 1997; Keck et al. 2007), and others deﬁned
relapse according to changes in scales such as the
Hamilton Rating Scale for Depression (HAMD),
Young Mania Rating Scale (YMRS), Mania Rating
Scale (MRS), and Montgomery–A˚sberg Depression
Rating Scale (MADRS) (e.g. Bowden et al. 2000b ;
Calabrese et al. 2005; Tohen et al. 2003, 2004, 2005,
2006 ; Vieta et al. 2008a). Even where the same scales
were used, the cut-oﬀ values were not necessarily the
same. For example, Tohen et al. (2003, 2004, 2005, 2006)
deﬁned relapse to mania as YMRSo15, whereas, Vieta
and colleagues deﬁned patients with YMRS>12 as
having a recurrence (Vieta et al. 2008a). A further
consideration is that there was no adjustment for
study duration and thus exposure to treatment.
The eﬃcacy seen with the atypical antipsychotics –
aripiprazole, olanzapine, quetiapine, risperidone, and
ziprasidone – as maintenance therapies must be bal-
anced against their side-eﬀect proﬁles. While it was
beyond the scope of this particular meta-analysis to
analyse all the safety and tolerability issues involved
in bipolar disorder maintenance trials, the data
indicate that aripiprazole is associated with tremor,
akathisia, dry mouth, and weight gain (Keck et al.
2007). Trial data for olanzapine show that treatment is
associated with somnolence, increased appetite, dry
mouth, sedation, weight gain, tremor, asthenia, diar-
rhoea, hyperprolactinaemia and nausea (Tohen et al.
2005, 2006). Quetiapine, as a maintenance treatment, is
associated with dry mouth, sedation, somnolence,
dizziness, constipation, extrapyramidal side-eﬀects,
and increases in weight compared to placebo (Suppes
et al. 2009; Vieta et al. 2008b). Trial data for risperidone
as maintenance treatment indicate that it is associated
Fig. 3b. Relative risk of depressive relapse – combination therapies. Heterogeneity : 4, quetiapine+Li/DVP (I2=0.0) ; overall
(I2=35.1%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence interval ; DVP, divalproex ; Li, lithium; OLZ, olanzapine ;
OXC, oxcarbazepine ; PPZ, perphenazine ; QTP, quetiapine ; RLAI, risperidone long-acting injectable ; ZIP, Ziprasidone.
(Perphenazine was excluded from the analysis, as there were no depressive relapses in the control group.)
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with weight gain and hyperprolactinaemia (Quiroz
et al. 2010). Long-term ziprasidone treatment is as-
sociated with weight gain (Bowden et al. 2010). There
are also concerns of increased risk of metabolic
syndrome – characterized by obesity, insulin resist-
ance, hypertension, and dyslipidaemia – with atypical
antipsychotics (Baptista et al. 2004). It is important to
be aware, however, that adverse events occurring
during maintenance treatment may diﬀer from those
observed in patients treated with agents for the ﬁrst
time.
In regard to the question as to whether there is a
rationale for distinguishing between drugs with dif-
ferent mechanisms of action as maintenance treatment
options, the ﬁndings from this meta-analysis suggest a
blurring of the lines between drugs with diﬀerent
mechanisms of action and their potential uses for this
indication. The ﬁndings have conﬁrmed the eﬃcacy of
lithium, widely viewed as a ‘mood stabilizer ’ as ef-
fective in the maintenance phase of bipolar disorder.
Aripiprazole, olanzapine and quetiapine, which are
classed as ‘antipsychotics ’ also show ‘mood stabiliz-
ing’ eﬃcacy in patients who have responded to them
during an acute episode. These ﬁndings suggest that
the original drug classiﬁcation of ‘antipsychotic ’ may
be misleading, and that treatment decisions should be
made regarding each individual agent rather than
viewing them as particular drug classes.
As for the question of whether any drugs show ef-
ﬁcacy against the recurrence of manic/mixed and de-
pressed mood events (i.e. at both poles of bipolar
illness), the ﬁndings from this analysis show that
only combination therapy with quetiapine+lithium/
divalproex was associated with reduced risk for re-
lapse at both the manic/mixed and depressed poles of
bipolar illness.
Fig. 4a. Relative risk of discontinuation – monotherapies. Heterogeneity : 3, lamotrigine (I2=0.0%) ; 4, lithium (I2=0.0%) ;
6, quetiapine (I2=0.0%) ; 7, quetiapine (I2=0.0%) ; overall (I2=64.0%). Dosages are in mg/d. RR, Relative risk ; CI, conﬁdence
interval ; ARP, aripiprazole ; DVP, divalproex ; LTG, lamotrigine ; Li, lithium; OLZ, olanzapine ; QTP, quetiapine ; RLAI,
risperidone long-acting injectable.
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Conclusions
This meta-analysis indicates that there are several
options available for the long-term treatment of
bipolar disorder, although considerable variation in
the eﬃcacy proﬁle exists among bipolar maintenance
therapies. The long-term eﬃcacy of lithium and
divalproex has been conﬁrmed, and some atypical
antipsychotics, such as aripiprazole, olanzapine,
quetiapine, and risperidone are also eﬀective in pre-
venting depressive or manic/mixed relapses. Neither
lamotrigine nor oxcarbazepine showed a RR below
1.0 for either manic/mixed or depressive relapse,
providing little support for these agents used
as monotherapies. For the combination therapies,
ziprasidone+lithium/divalproex and risperidone+
lithium/divalproex signiﬁcantly reduced the risk of
a manic relapse, but only quetiapine+lithium/
divalproex signiﬁcantly reduced risk for relapse at
both the manic/mixed and depressed poles of bipolar
illness. Interventions with proven eﬃcacy could
be considered appropriate options as ﬁrst-line main-
tenance treatment but their eﬃcacy will need to be
balanced against safety and tolerability issues.
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